Dr Kuno van der Post
OmniComm Systems, Inc.
2013 Innovation Award Recipients Announced
Fort Lauderdale, FL, November 22, 2013 – OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, celebrated innovation and excellence at their annual Innovation Forum in Ft. Lauderdale last week.
The 2013 Innovation Forum was the largest in OmniComm’s history with over 100 participants from around the globe representing OmniComm, their user community, and partner ecosystem. The two-day program highlighted recent industry changes and recognized cutting-edge innovations that directly impact clients and the entire Life Sciences community. The agenda featured several leading experts, client case studies, “hot topic” panel discussions and hands-on product specific breakout sessions. Keynote speakers included: David Jordan, Ph.D. from TransCelerate BioPharma, focusing on data & therapeutic standards development; Teri Stokes, Ph.D., an internationally recognized expert in the field of computer validation from GXP International; and Len Grunbaum of Practical Solutions, an authority on regulatory audits and compliance.
“This is an exciting time of expansion, enhancement and innovation at OmniComm and we were pleased to welcome many more attendees to this year’s meeting,” stated Dr. Kuno van der Post, OmniComm’s SVP of Business Development. “Not only did the Forum allow us to share our plans with many of our clients and partners, but more importantly, it allowed them to directly contribute through sharing their experiences and needs. This valuable feedback ensures that we will continue to enhance our customer experience and better align our product development pathways.”
OmniComm previewed a variety of new product features across all of the Company’s product lines that will be released later this year including an improved 100% automated SDTM mapping interface, tools to support risk-based and centralized monitoring, a new eClinical portal, web-based dual-data entry capability, and new functionality that accelerates the building of EDC studies.
OmniComm also took the opportunity to unveil its latest acquisition, Promasys B.V. Based in the Netherlands with offices in Japan, Promasys has clients in Japan, China, Korea, India, and Northern Europe. With this acquisition, OmniComm not only gains entry into the AsiaPac market, but also adds a new product line exclusively focused on electronic data collection within the academic research and investigator initiated trial environments.
“In addition to the expansion of our EDC product portfolio with the acquisition of Promasys, we were pleased to announce the expansion of our service offerings with the launch of our newest division, OmniComm’s Transformation Services,” stated Stephen Johnson, OmniComm’s President and COO. OmniComm’s Transformation Services group is dedicated to assisting organizations transform their clinical operations through business optimization, technology innovation, and application integration. “We wanted to offer our clients the opportunity to benefit from our decades of industry expertise.”
At this year’s Innovation Forum, OmniComm introduced the Innovation and Excellence Awards, recognizing innovative applications of OmniComm technologies and services. Nominees selected to receive this award demonstrated excellence in innovation resulting in improved organizational efficiencies and best practices.
OmniComm congratulates the inaugural Innovation & Excellence Award recipients:
- OPKO Health, Inc. (NYSE: OPK) – for their Risk-Based Monitoring (RBM) strategy and subsequent development of a process and program to validate its use. Using the recent FDA guidance, OPKO has incorporated RBM into EDC to focus its source verification on critical items and to monitor more effectively clinical trial data important for determining safety and efficacy.
- Prism Clinical Research – for their development of a new module for TrialOne® that allows subjects to register their interest for specific clinical trials. The new module includes a web service for advertised trials, customizable registration forms for general contact information and detailed forms for trial specific questionnaires. All collected data is seamlessly incorporated in the recruitment database for coordinator review.
- Additionally, a global pharmaceutical organization was recognized for their development of an innovative new registry database within TrialMaster®. The implementation of this database will help to improve overall site compliance for data collection.
About OmniComm Systems
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.